source
- BMS reports early Alzheimer’s psychosis data for Cobenfy showing reduced hallucinations but safety concerns remainAt the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Bristol Myers Squibb presented early Phase 3 ADEPT data for KarXT, marketed as Cobenfy, in patients with Alzheimer’s disea…
- Government policies strain funding and operations for small biotech firmsCassel Salpeter's latest healthcare investment report says that recent government actions, including FDA staff reductions, slower federal research grants and higher tariffs, are creating a tough fu…